Actively building life science companies

5AM Ventures is a leading venture capital firm focused on building next-generation life science companies capable of delivering outstanding returns to our investors.

Scroll to experience 5AM Ventures

Supporting companies that are working to solve important healthcare needs via cutting-edge breakthroughs in medicine and science.

Read Me

IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment
Read Me

Cleave Therapeutics Announces Commencement of a Phase I Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Read Me

scPharmaceuticals Announces FDA Acceptance of FUROSCIX® New Drug Application Resubmission
Read Me

Nouscom Highlights Cutting-Edge Science That Led to the Design of NOUS-209, A Potential Off-The-Shelf Neoantigen Cancer Vaccine for Tumors with Microsatellite Instability
Read Me

Homology Medicines Appoints Jeff Poulton to the Board of Directors

Pushing the healthcare industry forward

$ 0 B

UNDER MANAGEMENT

We’re a life science venture capital firm founded in 2002 and currently investing $350M from 5AM Ventures VI and $147M from 5AM Opportunities I.
0

PORTFOLIO COMPANIES

Our focus is biopharmaceuticals, drug delivery technologies and life science instruments.
0

ONGOING CLINICAL TRIALS

Our portfolio companies currently have over 18,000 patients enrolled across 750 test sites in ongoing clinical trials.

San Francisco, CA

Boston, MA